Kisspeptin peptide: hormonal health guide

Key takeaways

Kisspeptin is a naturally occurring neuropeptide that sits upstream of the entire reproductive hormone cascade, triggering GnRH release from the hypothalamus
It has been tested in multiple human clinical trials for fertility, IVF support, and hormonal disorders
Kisspeptin stimulates LH, FSH, and testosterone release in both men and women within minutes of administration
A kisspeptin receptor agonist (MVT-602) has progressed through randomized placebo-controlled trials
Research is rapidly expanding, including a 2025 study showing intranasal kisspeptin works in humans

Kisspeptin is a peptide hormone produced primarily in the hypothalamus that acts as the master switch for reproductive hormone signaling. Discovered in 2003, it binds to the KISS1R (GPR54) receptor on GnRH neurons and triggers the release of gonadotropin-releasing hormone (GnRH). Everything downstream follows: GnRH stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, which in turn drive testosterone production in men and estrogen/progesterone cycling in women.

The name has nothing to do with the peptide’s function. It was named after Hershey Kisses, because the gene was discovered at Penn State University in Hershey, Pennsylvania.

What makes kisspeptin unusual among research peptides is the pace of clinical translation. Unlike many compounds covered in peptide therapy guides that remain stuck at the animal study stage, kisspeptin has been administered to hundreds of human subjects in controlled clinical trials. A 2025 systematic review catalogued over 60 clinical studies involving kisspeptin in humans [1].

How does kisspeptin work?

Kisspeptin neurons in the hypothalamus act as integrators of metabolic, environmental, and hormonal signals. When conditions are right for reproduction (adequate energy stores, appropriate day length, absence of extreme stress), kisspeptin neurons fire and release the peptide onto nearby GnRH neurons.

This activation is fast. In human studies, intravenous kisspeptin bolus doses produce measurable LH rises within 30-60 minutes [2]. The effect on GnRH is pulsatile, mimicking the body’s natural secretion pattern rather than producing a sustained flood of hormone.

The kisspeptin system explains several previously mysterious reproductive phenomena. Why does extreme dieting stop menstrual cycles? Because low energy availability suppresses kisspeptin neuron activity. Why does chronic stress reduce testosterone? Because cortisol inhibits kisspeptin signaling. The peptide sits at the intersection of metabolism and reproduction.

Kisspeptin also appears to have effects beyond reproduction. A 2024 study found kisspeptin modulated food intake and locomotor activity in mice, independent of its reproductive effects [3]. In humans, a 2025 study showed kisspeptin administration increased oxytocin levels, with stronger effects in women than men [4]. These findings suggest the peptide’s role is broader than originally thought.

For context on where kisspeptin fits among hormonal peptides, see our guides on peptides for testosterone and peptides for libido.

Benefits supported by clinical evidence

Fertility and IVF

The most advanced clinical application is in assisted reproduction. Kisspeptin can trigger oocyte maturation in IVF protocols, potentially replacing the standard hCG trigger shot. The advantage: kisspeptin produces a more physiological LH surge with lower risk of ovarian hyperstimulation syndrome (OHSS), a dangerous complication of standard IVF protocols.

A kisspeptin receptor agonist called MVT-602 completed Phase I randomized placebo-controlled trials in healthy premenopausal women. Abbara et al. reported in Fertility and Sterility (2024) that single doses of MVT-602 produced dose-dependent increases in LH, FSH, estradiol, and progesterone, with peak LH responses occurring 8-12 hours after dosing [5].

Testosterone stimulation in men

Kisspeptin administration reliably increases testosterone in men through the LH pathway. A 2025 randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism showed that kisspeptin stimulated reproductive hormones in both men and women, with LH increases ranging from 2-8 fold depending on dose and timing [2].

This is relevant for men interested in testosterone support through natural pathway activation rather than exogenous testosterone replacement.

Intranasal delivery breakthrough

A 2025 study published in EBioMedicine demonstrated that intranasal kisspeptin rapidly stimulated gonadotropin release in humans [6]. This is significant because it opens the door to non-injectable administration. Mills et al. showed that a single intranasal dose produced measurable LH increases within 30 minutes, comparable to intravenous administration. The study was a randomized controlled trial with 37 participants.

For those interested in non-injection delivery methods, our guide on peptide nasal sprays covers the broader options.

Neuroendocrine effects

Beyond reproduction, kisspeptin influences oxytocin release. Galbiati et al. (2025) found sex-dependent increases in oxytocin after intravenous kisspeptin in a Phase I clinical trial, with women showing stronger oxytocin responses than men [4]. Interestingly, kisspeptin did not affect vasopressin levels in the same study population [7].

A separate randomized controlled trial found that kisspeptin stimulated reproductive hormones without increasing anxiety scores, which had been a theoretical concern [2].

Side effects and safety

Kisspeptin has a cleaner safety record than most peptides in the research pipeline, largely because of the number of human trials conducted.

Across clinical studies, commonly reported effects include:

Facial flushing is the most frequent side effect, reported in approximately 15-30% of subjects receiving intravenous kisspeptin. It is transient and resolves within minutes.

Mild injection site reactions occur with subcutaneous dosing. Headache is reported occasionally. No serious adverse events have been attributed to kisspeptin in published clinical trial data.

The theoretical concern with kisspeptin is desensitization. Continuous kisspeptin signaling can actually suppress GnRH release rather than stimulate it, a phenomenon used therapeutically in conditions like precocious puberty and endometriosis. Pulsatile dosing avoids this problem, but sustained-release formulations could potentially cause temporary reproductive hormone suppression.

For women, the main safety consideration in fertility applications is the risk of multiple follicle development. For men, there are no reported testosterone-suppressive effects from short-term pulsatile administration.

General safety considerations for injectable peptides are covered in our peptide side effects guide.

Dosage and administration

Clinical trial protocols have used several dosing approaches:

Intravenous bolus doses in research settings typically range from 0.24-13.5 nmol/kg of kisspeptin-54 or 0.03-1.0 nmol/kg of kisspeptin-10. These are research protocols administered under medical supervision.

The intranasal formulation tested by Mills et al. used 40 nmol of kisspeptin in a single intranasal administration [6].

The MVT-602 receptor agonist was tested at oral and subcutaneous doses in the Phase I trials, with specific dosing information available in the published trial data [5].

Kisspeptin is not available as a standard prescription medication. These dosing protocols are drawn from clinical trial publications and are not treatment recommendations. For guidance on peptide administration methods, see our guides on how to inject peptides and peptide injections.

Research and clinical trials

Current clinical development

Kisspeptin research is unusually active for a peptide compound. The systematic review by Velmurugan et al. (2025) in Current Medicinal Chemistry found 64 clinical studies examining kisspeptin in humans across fertility, endocrinology, and neuroscience applications [1].

Key active research areas include:

The group at Imperial College London (led by Waljit Dhillo and Ali Abbara) has conducted the largest body of clinical kisspeptin research, including the intranasal delivery study and the anxiety/reproductive hormone trial [2, 6].

Harvard/Massachusetts General Hospital (led by Elizabeth Lawson and Stephanie Seminara) has focused on kisspeptin’s neuroendocrine effects beyond reproduction, including the oxytocin findings [4, 7].

Drug development pipeline

MVT-602, a synthetic kisspeptin receptor agonist developed by Myovant Sciences, completed Phase I clinical trials. The compound was designed to have longer duration of action than native kisspeptin, which is rapidly degraded in blood [5]. Whether MVT-602 advances to Phase II trials will determine whether kisspeptin-based therapeutics reach the market.

Understanding puberty and reproductive disorders

Kisspeptin research has reshaped how endocrinologists understand puberty. Loss-of-function mutations in the KISS1R gene cause hypogonadotropic hypogonadism (failure to enter puberty), while gain-of-function mutations cause precocious puberty. A 2025 pilot study examined kisspeptin levels in girls with suspected precocious puberty, further connecting the peptide to pubertal timing [8].

How to get kisspeptin

Kisspeptin is not FDA-approved for any indication. It is available through some compounding pharmacies and research peptide suppliers, though availability varies.

The peptide’s clinical trial momentum suggests eventual FDA approval is possible, particularly for fertility applications. For now, access requires a physician willing to prescribe it off-label or participation in a clinical trial.

Individuals interested in hormonal optimization through peptide therapy have several options with stronger prescribing precedent. Sermorelin, CJC-1295 + ipamorelin, and other growth hormone secretagogues are more widely available through peptide therapy clinics. For testosterone-specific concerns, our guide on peptides for testosterone covers currently available options.

Those interested in pursuing kisspeptin specifically should seek a reproductive endocrinologist or a peptide therapy consultation with a provider tracking the latest clinical data.

Frequently asked questions

What does kisspeptin do in the body?▼

Kisspeptin triggers the release of GnRH from the hypothalamus, which starts the entire reproductive hormone cascade. It controls LH, FSH, testosterone, and estrogen production. It also influences oxytocin levels and may affect appetite and metabolism.

Can kisspeptin increase testosterone?▼

Yes. Clinical trials have demonstrated that kisspeptin administration increases LH, which in turn stimulates testosterone production in men. The effect is rapid (within hours) and dose-dependent [2]. However, it is not yet an approved treatment.

How is kisspeptin different from clomiphene or hCG for testosterone?▼

Clomiphene blocks estrogen feedback to increase LH. HCG mimics LH directly. Kisspeptin works upstream of both by stimulating the body’s own GnRH release, producing a more physiological hormonal cascade. The advantage is a more natural pulsatile hormone pattern. The disadvantage is shorter duration of action and lack of approved formulations.

Can kisspeptin help with fertility?▼

Kisspeptin is being actively investigated as an IVF trigger. It may reduce the risk of ovarian hyperstimulation syndrome compared to standard hCG triggers. Multiple clinical trials support its ability to trigger oocyte maturation [5]. It is not yet approved for this use.

Is kisspeptin available as a nasal spray?▼

An intranasal formulation was tested in a 2025 randomized controlled trial and showed effective gonadotropin stimulation [6]. This formulation is not commercially available but represents a promising non-injectable delivery route.

What are the side effects of kisspeptin?▼

The most common side effect in clinical trials is facial flushing (15-30% of subjects), which resolves quickly. Mild headache and injection site reactions have been reported. No serious adverse events have been attributed to kisspeptin in published clinical data.

Is kisspeptin the same as GnRH?▼

No. Kisspeptin stimulates the release of GnRH, but they are different molecules with different receptors. Kisspeptin works upstream, acting as the trigger for GnRH secretion rather than directly activating GnRH receptors on the pituitary.

Can kisspeptin be used for weight loss?▼

Animal studies suggest kisspeptin may modulate food intake and metabolism [3], but there is no clinical evidence supporting kisspeptin as a weight loss treatment in humans. For weight management peptides, see our guide on peptides for weight loss.

References

Velmurugan H, Mannava AS, Thangaraju P, Neelambaran K. Kisspeptin and its Current Clinical Status-A Systematic Review. Curr Med Chem. 2025;32(7):1313-1322. PubMed
Mills EG, Thurston L, Yang L, et al. Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans. J Clin Endocrinol Metab. 2025;110(11):3133-3141. PubMed
Velasco I, Daza-Dueñas S, Torres E, et al. Kisspeptins centrally modulate food intake and locomotor activity in mice independently of gonadal steroids in a sexually dimorphic manner. J Neuroendocrinol. 2024;36(10):e13433. PubMed
Galbiati F, Plessow F, Plummer L, et al. Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans. Eur J Endocrinol. 2025;192(3):K24-K29. PubMed
Abbara A, Ufer M, Voors-Pette C, et al. Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation. Fertil Steril. 2024;121(1):95-106. PubMed
Mills EG, Silva MSB, Delli V, et al. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine. 2025;115:105689. PubMed
Galbiati F, Plessow F, Plummer L, et al. Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans. J Neuroendocrinol. 2026;38(1):e70114. PubMed
Rodanaki M, Rask E, Lodefalk M. Effect of a GnRH injection on kisspeptin levels in girls with suspected precocious puberty: a randomized-controlled pilot study. J Pediatr Endocrinol Metab. 2025;38(3):288-291. PubMed